Wednesday, May 01, 2019 3:23:18 PM
https://www.streetwisereports.com/article/2019/05/01/pivotal-topline-up-next-for-biotechs-phase-3-cardiac-clinical-trial.html
Read the disclaiming statement about Roth at the end....I think that might be an indication of an eventual US listing, hopefully Nasdaq.
If you want to taste the fruit, you have to go out on a limb. But if you wait for the herd to move out on the limb....the branch tends to snap.
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
HealthLynked Corp Announces Chris Hall as New Chief Technology Officer • HLYK • Mar 19, 2024 8:00 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM